source
- FDA schedules advisory committee meetings for rejected Replimune melanoma drug and Capricor DMD cell therapyThe FDA announced that it will hold two advisory committee meetings this week to revisit investigational therapies that were previously turned down. One meeting will consider Capricor Therapeutics'…
- Sanofi scraps most atopic dermatitis trials after amlitelimab fails to outperform standard careSanofi announced it is halting all but one ongoing trial for amlitelimab, an OX40‑ligand antibody acquired through its $1.4 billion purchase of Kymab. The decision follows the Phase 3 COAST‑1 stud…